Authored by Cello Health BioConsulting, now part of Lumanity
I’m no fortune-teller. But I can predict with a reasonable amount of certainty that, in the next week or so, we’ll see a press release that more or less says the following: “Mega venture round for CAR-T therapy platform company coming out of stealth-mode with an A-list cadre of scientific co-founders, a C-suite that knows how to raise funds and get the job done, and a value proposition pointed at the target painted on the backs of early-mover products.” While money is clearly not falling from the sky, there are massive opportunities for cell therapy newcos with their ducks in a row.
Read the full article
To read the full article, please complete the form below.
"*" indicates required fields